CRISPR Therapeutics has reported one-year Phase 1a data showing that a single infusion of CTX310 produced deep and sustained reductions in ANGPTL3, triglycerides and low-density lipoprotein cholesterol across patients with difficult-to-control lipid disorders. At the highest tested dose, mean ANGPTL3 levels fell 79%, triglycerides declined 48% and LDL cholesterol dropped 53%, with the effects maintained through at least one year of follow-up. The findings were presented during a late-breaking session at the European Society of Cardiology Congress and add durability evidence to an in vivo gene-editing program that CRISPR Therapeutics is now advancing through Phase 1b development.
The importance of the update lies less in demonstrating that CTX310 can lower lipids, which earlier data had already suggested, and more in showing that the effect persists after a one-time treatment. CRISPR Therapeutics is attempting to develop cardiovascular therapies that permanently modify disease-related genes rather than requiring patients to remain on daily tablets or repeated injections for decades. The durability shown so far strengthens that concept, although CTX310 remains an early-stage program involving only 15 Phase 1a participants and will require considerably larger studies before its cardiovascular benefit and long-term safety can be established.
One CTX310 infusion maintains substantial ANGPTL3 and lipid reductions through one year
CTX310 is an investigational in vivo CRISPR/Cas9 therapy designed to disrupt ANGPTL3 in liver cells. ANGPTL3 normally inhibits enzymes involved in lipid metabolism, and naturally occurring loss-of-function variants in the gene have been associated with lower LDL cholesterol, lower triglycerides and reduced lifetime risk of atherosclerotic cardiovascular disease. CRISPR Therapeutics is attempting to reproduce that protective biology through a one-time gene-editing treatment.
The Phase 1a dose-escalation study treated 15 participants with uncontrolled lipid disorders despite background standard-of-care therapy. Eligible patients included individuals with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, severe hypertriglyceridemia or mixed dyslipidemia. Most participants were already receiving statins or ezetimibe, while 40% were using PCSK9 inhibitors, meaning CTX310 was being tested in patients whose lipid levels remained difficult to control despite conventional treatment.
Patients received a single intravenous dose ranging from 0.1 to 0.8 milligrams per kilogram of lean body weight. The latest update confirms that dose-dependent suppression of ANGPTL3 remained evident through one year, with patients at the 0.8 milligram-per-kilogram dose achieving a mean ANGPTL3 reduction of 79% and a maximum reduction of 89%. Mean triglycerides fell 48%, with the largest individual reduction reaching 78%, while mean LDL cholesterol declined 53% and the maximum reduction reached 84%.
Those findings are significant because durability is central to the rationale for permanent gene editing. Existing cholesterol and triglyceride therapies can be highly effective, but their benefits depend on continued dosing and adherence. A treatment capable of producing substantial lipid reductions for years after one administration could create a fundamentally different treatment model, particularly for patients with severe inherited or refractory lipid disorders.
Durable lipid lowering strengthens the one-time treatment thesis but the Phase 1 sample remains small
Earlier results published in The New England Journal of Medicine had already demonstrated substantial ANGPTL3 reductions at the higher CTX310 doses. The original Phase 1 report found mean ANGPTL3 reductions approaching 80% at the 0.7-milligram-per-kilogram level and more than 70% at 0.8 milligrams per kilogram during shorter follow-up. The latest data extend those findings by showing that editing and downstream lipid effects have not meaningfully faded after one year.
That persistence is biologically consistent with CRISPR/Cas9 editing because CTX310 is intended to permanently disrupt ANGPTL3 within hepatocytes rather than temporarily suppress the circulating protein. If the edited liver-cell population remains stable, sustained effects could theoretically continue for substantially longer than one year.
The current evidence nevertheless leaves important unanswered questions. Only 15 people participated in Phase 1a, and the trial was open-label without a placebo or active comparator. The patient population was also heterogeneous, spanning several different lipid disorders, which makes it difficult to determine how consistently individual disease groups will respond.
More importantly, reduction in ANGPTL3 or LDL cholesterol is not the same as demonstrating fewer heart attacks, strokes or cardiovascular deaths. Those lipid changes are biologically encouraging and potentially clinically important, but future development will need to determine whether permanent ANGPTL3 editing ultimately delivers a favorable long-term benefit-risk profile.
Questions surrounding irreversible gene editing are likely to receive particular scrutiny in cardiovascular medicine because patients may otherwise have decades of life ahead of them. A commentary published in The New England Journal of Medicine earlier this year highlighted the need for caution around long-term hepatic safety and irreversible editing when applying such technologies to common cardiometabolic diseases.
Safety remains encouraging through extended follow-up as CRISPR Therapeutics moves into Phase 1b
CRISPR Therapeutics said no new treatment-related adverse events emerged during the extended follow-up period. There were no treatment-related serious adverse events, no dose-limiting toxicities and no Grade 3 or higher changes in liver transaminases.
Previously reported events included an allergic reaction in one participant that resolved with supportive care and Grade 2 infusion reactions in three patients. One participant with elevated liver enzymes at baseline experienced a temporary further increase after treatment, but the levels returned to baseline within approximately two weeks. No additional liver-function abnormalities were reported during subsequent follow-up.
Longer observation remains essential because one of the principal questions surrounding permanent in vivo editing is whether unexpected safety effects could emerge months or years after treatment. The absence of additional treatment-related events through one year is reassuring, but it cannot yet establish the long-term safety profile necessary for widespread cardiovascular use.
CRISPR Therapeutics has already moved CTX310 into Phase 1b testing using a fixed dose corresponding to the most effective 0.8-milligram-per-kilogram Phase 1a exposure. The company expects another update during the second half of 2026, with particular focus on patients with severe hypertriglyceridemia.
That cohort could help clarify where CTX310 initially fits best. Rather than immediately pursuing broad cholesterol lowering in millions of patients, CRISPR Therapeutics appears to be concentrating first on severe conditions where existing therapies leave substantial residual risk and where the potential advantages of permanent editing may justify a higher threshold for intervention.
CTX310 forms part of a broader cardiovascular gene-editing strategy at CRISPR Therapeutics
The significance of CTX310 also extends beyond ANGPTL3. CRISPR Therapeutics has developed a lipid nanoparticle delivery system intended to transport gene-editing machinery directly to the liver, creating a technology base that the company is applying across several cardiovascular targets.
Its current in vivo cardiovascular portfolio includes CTX340 targeting angiotensinogen for refractory hypertension and CTX321 targeting LPA for patients with elevated lipoprotein(a). CRISPR Therapeutics is therefore testing whether the delivery and editing infrastructure established with CTX310 can support multiple one-time cardiovascular treatments rather than a single isolated product.
That strategy would represent a substantial expansion beyond the company’s existing commercial exposure to CASGEVY, the ex vivo CRISPR-edited therapy developed with Vertex Pharmaceuticals. Whereas CASGEVY requires stem cells to be removed, edited outside the body and reinfused, CTX310 delivers CRISPR components directly into the patient, making successful in vivo editing potentially applicable to considerably larger disease populations.
CRISPR Therapeutics also enters this development phase with a strong balance sheet. The company ended June with approximately $2.36 billion in cash, cash equivalents and marketable securities, up from about $1.98 billion at the end of 2025, providing substantial resources to advance multiple clinical programs.
CRISPR Therapeutics shares remain volatile as investors wait for broader Phase 1b evidence
CRISPR Therapeutics shares were trading near $58.22 during morning trading on August 28, down about 1.9%, despite the positive durability update. The stock had already gained 6.7% on August 25 as investors positioned ahead of the European Society of Cardiology presentation, suggesting that at least part of the encouraging CTX310 outcome may have been anticipated before the detailed data arrived.
The muted response also reflects the early stage of the program. One-year durability is important, but investors now have additional questions to answer, including whether efficacy remains consistent in larger cohorts, whether Phase 1b data confirm the safety profile and how regulators ultimately view irreversible editing for chronic cardiovascular disease.
The next severe hypertriglyceridemia update could therefore carry more weight than the August durability presentation because it should provide additional patients treated at the selected clinical dose and begin defining the population CRISPR Therapeutics may prioritize for later-stage development.
CTX310 has now demonstrated that a single in vivo CRISPR treatment can generate substantial ANGPTL3 and lipid reductions lasting at least one year. The larger challenge is converting that biological durability into a therapy with sufficiently predictable efficacy and long-term safety to justify permanently editing a cardiovascular target. Phase 1b development will begin determining whether the program can make that transition.
